Measuring a panel of biomarkers of insulin sensitivity and insulin resistance has the potential to provide new comprehensive assessments of alterations in biological processes and changes in underlying mechanisms of glucose regulation, permit early detection and screening of insulin resistance thereby allowing for early intervention and therapeutic monitoring, and contribute to personalised medicine and optimization of exercise prescriptions for space agencies and public health agencies. The gene discussed is INS; the disease is Insulin resistance.